Pharmaceutical development is governed not only by scientific discovery, but by the regulatory evidence required to establish quality, safety, efficacy and responsible clinical use. Written for B.Pharm Semester VII students under the PCI 2026 framework, this textbook develops Regulatory Affairs as an applied pharmaceutical discipline linking drug development, regulatory decision-making and protection of public health.The text progresses from regulatory principles, terminology and major authorities to drug discovery, non-clinical evaluation, regulatory documentation and clinical development.
It examines CDSCO and State Licensing Authorities in India, international agencies including the US FDA, EMA and PMDA, IND, NDA and ANDA pathways, Drug Master Files, bioequivalence, generic and phytopharmaceutical regulation, CTD, eCTD and ACTD submissions, overseas registration and post-approval changes. Clinical research phases, IRB and IEC functions, informed consent, Good Clinical Practice, trial monitoring and pharmacovigilance are integrated within the wider product lifecycle.
Clear explanations emphasise why regulatory requirements exist, how evidence is generated and documented, and how regulators use that evidence in review and approval. Jurisdiction-specific concepts are carefully distinguished, while historical provisions are placed in appropriate context.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
HRD. Etat : New. New Book. Shipped from UK. Established seller since 2000. N° de réf. du vendeur L2-9798907224193
Quantité disponible : Plus de 20 disponibles
Vendeur : California Books, Miami, FL, Etats-Unis
Etat : New. N° de réf. du vendeur I-9798907224193
Quantité disponible : Plus de 20 disponibles
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Pharmaceutical development is governed not only by scientific discovery, but by the regulatory evidence required to establish quality, safety, efficacy and responsible clinical use. Written for B.Pharm Semester VII students under the PCI 2026 framework, this textbook develops Regulatory Affairs as an applied pharmaceutical discipline linking drug development, regulatory decision-making and protection of public health.The text progresses from regulatory principles, terminology and major authorities to drug discovery, non-clinical evaluation, regulatory documentation and clinical development.It examines CDSCO and State Licensing Authorities in India, international agencies including the US FDA, EMA and PMDA, IND, NDA and ANDA pathways, Drug Master Files, bioequivalence, generic and phytopharmaceutical regulation, CTD, eCTD and ACTD submissions, overseas registration and post-approval changes. Clinical research phases, IRB and IEC functions, informed consent, Good Clinical Practice, trial monitoring and pharmacovigilance are integrated within the wider product lifecycle.Clear explanations emphasise why regulatory requirements exist, how evidence is generated and documented, and how regulators use that evidence in review and approval. Jurisdiction-specific concepts are carefully distinguished, while historical provisions are placed in appropriate context. N° de réf. du vendeur 9798907224193
Quantité disponible : 2 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Buch. Etat : Neu. Pharmaceutical Regulatory Affairs | Drug Development, Approval and Clinical Research For [.] Semester VII Course Code: BP707T | Putta Ravi (u. a.) | Buch | Englisch | 2026 | Notion Press | EAN 9798907224193 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. N° de réf. du vendeur 136960901
Quantité disponible : 5 disponible(s)